Sanofi Consumer (SANOFICONR) | Financial Analysis & Statements
Sanofi Consumer Healthcare Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
2.5B
Gross Profit
1.8B
72.79%
Operating Income
864.0M
34.42%
Net Income
665.0M
26.49%
EPS (Diluted)
₹28.87
Balance Sheet Metrics
Total Assets
5.5B
Total Liabilities
1.6B
Shareholders Equity
3.8B
Debt to Equity
0.42
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Sanofi Consumer Income Statement From 2023 to 2025
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 8.8B | 7.2B | 5.4B |
| Cost of Goods Sold | 2.3B | 2.3B | 1.9B |
| Gross Profit | 6.5B | 4.9B | 3.5B |
| Gross Margin % | 73.8% | 68.1% | 64.4% |
| Operating Expenses | |||
| Research & Development | - | - | - |
| Selling, General & Administrative | - | 724.0M | 647.0M |
| Other Operating Expenses | 2.1B | 472.0M | 231.0M |
| Total Operating Expenses | 2.1B | 1.2B | 878.0M |
| Operating Income | 3.0B | 2.7B | 2.2B |
| Operating Margin % | 33.8% | 37.2% | 39.9% |
| Non-Operating Items | |||
| Interest Income | - | 109.0M | 40.0M |
| Interest Expense | 20.0M | 40.0M | 2.0M |
| Other Non-Operating Income | - | - | - |
| Pre-tax Income | 3.2B | 2.5B | 2.2B |
| Income Tax | 802.0M | 658.0M | 544.0M |
| Effective Tax Rate % | 25.0% | 26.7% | 24.8% |
| Net Income | 2.4B | 1.8B | 1.6B |
| Net Margin % | 27.3% | 25.3% | 30.3% |
| Key Metrics | |||
| EBITDA | 3.3B | 2.8B | 2.2B |
| EPS (Basic) | - | ₹78.59 | ₹71.60 |
| EPS (Diluted) | - | ₹78.59 | ₹71.60 |
| Basic Shares Outstanding | - | 23030622 | 23030622 |
| Diluted Shares Outstanding | - | 23030622 | 23030622 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Sanofi Consumer Balance Sheet From 2023 to 2025
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Assets | |||
| Current Assets | |||
| Cash & Equivalents | 3.7B | 3.3B | 16.0M |
| Short-term Investments | 4.0M | 38.0M | - |
| Accounts Receivable | 296.0M | 137.0M | 316.0M |
| Inventory | 619.0M | 409.0M | 966.0M |
| Other Current Assets | 275.0M | 58.0M | - |
| Total Current Assets | 4.9B | 3.9B | 3.4B |
| Non-Current Assets | |||
| Property, Plant & Equipment | 351.0M | 272.0M | 0 |
| Goodwill | 8.0M | 19.0M | 55.0M |
| Intangible Assets | - | 19.0M | 55.0M |
| Long-term Investments | - | - | - |
| Other Non-Current Assets | - | - | - |
| Total Non-Current Assets | 527.0M | 396.0M | 102.0M |
| Total Assets | 5.5B | 4.3B | 3.5B |
| Liabilities | |||
| Current Liabilities | |||
| Accounts Payable | 796.0M | 703.0M | 600.0M |
| Short-term Debt | 77.0M | 37.0M | 0 |
| Current Portion of Long-term Debt | - | - | - |
| Other Current Liabilities | 30.0M | 39.0M | - |
| Total Current Liabilities | 1.3B | 1.3B | 1.3B |
| Non-Current Liabilities | |||
| Long-term Debt | 171.0M | 166.0M | 0 |
| Deferred Tax Liabilities | - | - | - |
| Other Non-Current Liabilities | - | - | - |
| Total Non-Current Liabilities | 346.0M | 277.0M | 79.0M |
| Total Liabilities | 1.6B | 1.6B | 1.4B |
| Equity | |||
| Common Stock | 230.0M | 230.0M | 20.0M |
| Retained Earnings | - | - | - |
| Treasury Stock | - | - | - |
| Other Equity | - | - | - |
| Total Shareholders Equity | 3.8B | 2.7B | 2.1B |
| Key Metrics | |||
| Total Debt | 248.0M | 203.0M | 0 |
| Working Capital | 3.7B | 2.6B | 2.1B |
Balance Sheet Composition
Sanofi Consumer Cash Flow Statement From 2023 to 2025
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating Activities | |||
| Net Income | 3.2B | 2.5B | 2.2B |
| Depreciation & Amortization | - | - | - |
| Stock-Based Compensation | -10.0M | 10.0M | 0 |
| Working Capital Changes | -679.0M | 2.9B | -2.2B |
| Operating Cash Flow | 2.4B | 5.3B | -55.0M |
| Investing Activities | |||
| Capital Expenditures | -76.0M | -99.0M | -40.0M |
| Acquisitions | - | - | - |
| Investment Purchases | - | - | - |
| Investment Sales | - | - | - |
| Investing Cash Flow | -76.0M | -99.0M | -40.0M |
| Financing Activities | |||
| Share Repurchases | - | - | - |
| Dividends Paid | -1.3B | -1.2B | - |
| Debt Issuance | - | - | - |
| Debt Repayment | - | - | - |
| Financing Cash Flow | -1.3B | -1.2B | 20.0M |
| Free Cash Flow | 1.7B | 4.3B | -44.0M |
| Net Change in Cash | 1.0B | 4.1B | -75.0M |
Cash Flow Trend
Sanofi Consumer Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
43.91
Forward P/E
34.17
Price to Book
27.44
Price to Sales
12.01
PEG Ratio
34.17
Profitability Ratios
Profit Margin
27.33%
Operating Margin
34.42%
Return on Equity
73.09%
Return on Assets
37.99%
Financial Health
Current Ratio
3.85
Debt to Equity
6.46
Per Share Data
EPS (TTM)
₹104.19
Book Value per Share
₹166.71
Revenue per Share
₹381.47
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| SANOFICONR | 105.9B | 43.91 | 27.44 | 73.09% | 27.33% | 6.46 |
| GlaxoSmithKline | 422.7B | 41.55 | 24.80 | 47.54% | 26.86% | 2.09 |
| Pfizer | 218.8B | 25.56 | 5.66 | 18.20% | 34.39% | 2.33 |
| Marksans Pharma | 86.2B | 23.96 | 3.20 | 15.29% | 12.85% | 12.24 |
| Sanofi India Limited | 79.3B | 24.31 | 10.59 | 40.59% | 17.78% | 2.38 |
| Senores | 41.0B | 35.50 | 5.54 | 7.21% | 18.36% | 28.90 |
Financial data is updated regularly. All figures are in the company's reporting currency.




